{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:06:36Z","timestamp":1786115196802,"version":"build-2736575974"},"reference-count":134,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006149","name":"Oxford University Hospitals NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006149","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kisupplements.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Supplements"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.kisu.2026.01.003","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:13:49Z","timestamp":1784538829000},"page":"3-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["IgA nephropathy: an overview of the disease, its pathophysiology, and involvement of the gut-kidney axis"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8593-7625","authenticated-orcid":false,"given":"Chee Kay","family":"Cheung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura H.","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kisu.2026.01.003_bib1","first-page":"694","article-title":"[Intercapillary deposits of IgA-IgG]","volume":"74","author":"Berger","year":"1968","journal-title":"J Urol Nephrol (Paris)"},{"key":"10.1016\/j.kisu.2026.01.003_bib2","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/ndt\/gfq665","article-title":"The incidence of primary glomerulonephritis worldwide: a systematic review of the literature","volume":"26","author":"McGrogan","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2026.01.003_bib3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41581-024-00885-3","article-title":"The pathogenesis of IgA nephropathy and implications for treatment","volume":"21","author":"Cheung","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kisu.2026.01.003_bib4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.003_bib5","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.34067\/KID.0000000000000165","article-title":"Global incidence of IgA nephropathy by race and ethnicity: a systematic review","volume":"4","author":"Kiryluk","year":"2023","journal-title":"Kidney360"},{"key":"10.1016\/j.kisu.2026.01.003_bib6","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1093\/ndt\/gfad082","article-title":"The incidence and prevalence of IgA nephropathy in Europe","volume":"38","author":"Willey","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2026.01.003_bib7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10157-015-1129-8","article-title":"Epidemiological survey and clinical investigation of pediatric IgA nephropathy","volume":"20","author":"Shibano","year":"2016","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.kisu.2026.01.003_bib8","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.semnephrol.2018.05.013","article-title":"Epidemiology of IgA nephropathy: a global perspective","volume":"38","author":"Schena","year":"2018","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.kisu.2026.01.003_bib9","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1093\/ckj\/sfad199","article-title":"Ethnicity and IgA nephropathy: worldwide differences in epidemiology, timing of diagnosis, clinical manifestations, management and prognosis","volume":"16","author":"Lee","year":"2023","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kisu.2026.01.003_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002765","article-title":"Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis","volume":"8","author":"Kiryluk","year":"2012","journal-title":"PLoS Genet"},{"key":"10.1016\/j.kisu.2026.01.003_bib11","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/nep.13592","article-title":"Is immunoglobulin A nephropathy different in different ethnic populations?","volume":"24","author":"Yeo","year":"2019","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.kisu.2026.01.003_bib12","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/s41588-023-01422-x","article-title":"Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy","volume":"55","author":"Kiryluk","year":"2023","journal-title":"Nat Genet"},{"key":"10.1016\/j.kisu.2026.01.003_bib13","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/j.ajkd.2021.01.024","article-title":"IgA nephropathy: core curriculum 2021","volume":"78","author":"Pattrapornpisut","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kisu.2026.01.003_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.572754","article-title":"Monitoring immune responses in IgA nephropathy: biomarkers to guide management","volume":"11","author":"Selvaskandan","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.kisu.2026.01.003_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ndt\/gfae151","article-title":"The use of albuminuria or proteinuria for risk prediction in IgAN","volume":"40","author":"Cheung","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2026.01.003_bib16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.kisu.2026.01.004","article-title":"Jain K, Rizk DV. The expanding role of biomarkers in the management of IgA nephropathy","volume":"15","year":"2026","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kisu.2026.01.003_bib17","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/ki.2015.322","article-title":"The MEST score provides earlier risk prediction in lgA nephropathy","volume":"89","author":"Barbour","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.003_bib18","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/ki.2009.243","article-title":"The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification","volume":"76","author":"Cattran","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.003_bib19","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/ki.2009.168","article-title":"The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility","volume":"76","author":"Roberts","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.003_bib20","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","article-title":"Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group","volume":"91","author":"Trimarchi","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.003_bib21","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.kint.2020.08.006","article-title":"Consensus definitions for glomerular lesions by light and electron microscopy: recommendations from a working group of the Renal Pathology Society","volume":"98","author":"Haas","year":"2020","journal-title":"Kidney Int"},{"issue":"4S","key":"10.1016\/j.kisu.2026.01.003_bib22","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.003_bib23","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.34067\/KID.0002972021","article-title":"The phenotypic difference of IgA nephropathy and its race\/gender-dependent molecular mechanisms","volume":"2","author":"Suzuki","year":"2021","journal-title":"Kidney360"},{"key":"10.1016\/j.kisu.2026.01.003_bib24","first-page":"21","article-title":"Chronic kidney disease: identification and management in primary care","volume":"7","author":"Fraser","year":"2016","journal-title":"Pragmat Obs Res"},{"key":"10.1016\/j.kisu.2026.01.003_bib25","doi-asserted-by":"crossref","first-page":"36","DOI":"10.36469\/jheor.2021.26129","article-title":"A systematic literature review of the epidemiology, health-related quality of life impact, and economic burden of immunoglobulin A nephropathy","volume":"8","author":"Kwon","year":"2021","journal-title":"J Health Econ Outcomes Res"},{"key":"10.1016\/j.kisu.2026.01.003_bib26","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.ekir.2018.07.021","article-title":"Clinical characteristics and treatment patterns of children and adults with IgA nephropathy or IgA vasculitis: findings from the CureGN study","volume":"3","author":"Selewski","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kisu.2026.01.003_bib27","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/ndt\/gfr527","article-title":"Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population","volume":"27","author":"Le","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2026.01.003_bib28","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/ki.2014.63","article-title":"Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments","volume":"86","author":"Coppo","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.003_bib29","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/ndt\/gfae085","article-title":"Albuminuria predicts kidney events in IgA nephropathy","volume":"40","author":"Faucon","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2026.01.003_bib30","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ekir.2017.08.008","article-title":"Life expectancy for patients from the southeastern United States with IgA nephropathy","volume":"3","author":"Hastings","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kisu.2026.01.003_bib31","doi-asserted-by":"crossref","first-page":"8660","DOI":"10.1681\/ASN.2018101017","article-title":"Mortality in IgA nephropathy: a nationwide population-based cohort study","volume":"30","author":"Jarrick","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.003_bib32","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1056\/NEJMra1206793","article-title":"IgA nephropathy","volume":"368","author":"Wyatt","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kisu.2026.01.003_bib33","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.kint.2022.02.042","article-title":"Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy","volume":"102","author":"Barbour","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.003_bib34","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1001\/jamainternmed.2019.0600","article-title":"Evaluating a new international risk-prediction tool in IgA nephropathy","volume":"179","author":"Barbour","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.kisu.2026.01.003_bib39","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.kisu.2026.01.002","article-title":"Canetta PA, Reich HN. Management of IgA nephropathy and the expanding role of immunomodulation","volume":"15","year":"2026","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kisu.2026.01.003_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.semnephrol.2025.151569","article-title":"IgAN across the age spectrum: the pediatric perspective","volume":"44","author":"Peruzzi","year":"2024","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.kisu.2026.01.003_bib41","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1007\/s00467-024-06361-1","article-title":"Are children with IgA nephropathy different from adult patients?","volume":"39","author":"Su","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kisu.2026.01.003_bib42","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1186\/s12882-022-03002-3","article-title":"Clinical manifestations and pathological correlation of immunoglobulin A nephropathy in children","volume":"23","author":"Sausukpaiboon","year":"2022","journal-title":"BMC Nephrol"},{"issue":"4S","key":"10.1016\/j.kisu.2026.01.003_bib43","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2025.04.004","article-title":"KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV)","volume":"108","author":"Rovin","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.003_bib44","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.kint.2020.10.033","article-title":"Updating the International IgA Nephropathy Prediction Tool for use in children","volume":"99","author":"Barbour","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.003_bib45","doi-asserted-by":"crossref","DOI":"10.1080\/0886022X.2024.2411846","article-title":"Predictive role of Oxford Classification for prognosis in children with IgA nephropathy: a systematic review and meta-analysis","volume":"46","author":"Liu","year":"2024","journal-title":"Ren Fail"},{"key":"10.1016\/j.kisu.2026.01.003_bib46","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3118","article-title":"Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens","volume":"46","author":"Kiryluk","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.kisu.2026.01.003_bib47","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/0886022X.2018.1532907","article-title":"The influence of environmental factors on clinical pathological changes of patients with immunoglobulin A nephropathy from different areas of China","volume":"40","author":"Fan","year":"2018","journal-title":"Ren Fail"},{"key":"10.1016\/j.kisu.2026.01.003_bib48","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1016\/j.ekir.2023.07.023","article-title":"Targeting the endothelin A receptor in IgA nephropathy","volume":"8","author":"Kohan","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kisu.2026.01.003_bib49","doi-asserted-by":"crossref","first-page":"458","DOI":"10.2215\/CJN.14031119","article-title":"GWAS-based discoveries in IgA nephropathy, membranous nephropathy, and steroid-sensitive nephrotic syndrome","volume":"16","author":"Sanchez-Rodriguez","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.003_bib50","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/ki.2015.149","article-title":"Gluten and IgA nephropathy: you are what you eat?","volume":"88","author":"Cheung","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.003_bib51","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/j.ekir.2020.08.009","article-title":"Why target the gut to treat IgA nephropathy?","volume":"5","author":"Barratt","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kisu.2026.01.003_bib52","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/iji.12561","article-title":"Immunological drivers of IgA nephropathy: exploring the mucosa-kidney link","volume":"49","author":"Selvaskandan","year":"2022","journal-title":"Int J Immunogenet"},{"key":"10.1016\/j.kisu.2026.01.003_bib53","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0272-6386(88)80024-6","article-title":"IgA nephropathy: clinical features and natural history--a pediatric perspective","volume":"12","author":"Hogg","year":"1988","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kisu.2026.01.003_bib54","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00467-012-2139-3","article-title":"Comparison of clinicopathological features between children and adults with IgA nephropathy","volume":"27","author":"Wang","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kisu.2026.01.003_bib55","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3390\/ijms24010574","article-title":"Gut microbiota alterations and primary glomerulonephritis in children: a review","volume":"24","author":"Kawalec","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.kisu.2026.01.003_bib56","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1681\/ASN.2020060848","article-title":"Inflammatory bowel disease is more common in patients with IgA nephropathy and predicts progression of ESKD: a Swedish population-based cohort study","volume":"32","author":"Rehnberg","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.003_bib57","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1681\/ASN.2011060567","article-title":"Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy","volume":"23","author":"Serino","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.003_bib58","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1016\/j.febslet.2015.10.033","article-title":"Increased miR-374b promotes cell proliferation and the production of aberrant glycosylated IgA1 in B cells of IgA nephropathy","volume":"589","author":"Hu","year":"2015","journal-title":"FEBS Lett"},{"key":"10.1016\/j.kisu.2026.01.003_bib59","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/ndt\/gfv032","article-title":"Role of let-7b in the regulation of N-acetylgalactosaminyltransferase 2 in IgA nephropathy","volume":"30","author":"Serino","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2026.01.003_bib60","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.ekir.2021.05.018","article-title":"A pilot study to predict risk of IgA nephropathy progression based on miR-204 expression","volume":"6","author":"Pawluczyk","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kisu.2026.01.003_bib61","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1042\/bj2710285","article-title":"The structure and function of human IgA","volume":"271","author":"Kerr","year":"1990","journal-title":"Biochem J"},{"key":"10.1016\/j.kisu.2026.01.003_bib62","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1365-2567.2001.01251.x","article-title":"Intraspecies heterogeneity of immunoglobulin alpha-chain constant region genes in rhesus macaques","volume":"103","author":"Scinicariello","year":"2001","journal-title":"Immunology"},{"key":"10.1016\/j.kisu.2026.01.003_bib63","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00281-021-00883-8","article-title":"IgA glycosylation and immune complex formation in IgAN","volume":"43","author":"Suzuki","year":"2021","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.kisu.2026.01.003_bib64","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41598-020-57510-z","article-title":"Analysis of O-glycoforms of the IgA1 hinge region by sequential deglycosylation","volume":"10","author":"Ohyama","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.kisu.2026.01.003_bib65","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1681\/ASN.2007091052","article-title":"Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy","volume":"19","author":"Gharavi","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.003_bib66","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/ndt\/gfaa352","article-title":"Mass spectrometry-based screening identifies circulating immunoglobulinA-alpha1-microglobulin complex as potential biomarker in immunoglobulin A nephropathy","volume":"36","author":"Xu","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2026.01.003_bib67","doi-asserted-by":"crossref","first-page":"297","DOI":"10.25259\/ijn_425_23","article-title":"IgA nephropathy: emerging mechanisms of disease","volume":"34","author":"Roberts","year":"2024","journal-title":"Indian J Nephrol"},{"key":"10.1016\/j.kisu.2026.01.003_bib68","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/ki.1986.274","article-title":"Sequential study of the IgA system in relapsing IgA nephropathy","volume":"30","author":"Feehally","year":"1986","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.003_bib69","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00281-021-00871-y","article-title":"The mucosal immune system and IgA nephropathy","volume":"43","author":"Gesualdo","year":"2021","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.kisu.2026.01.003_bib70","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.it.2024.01.006","article-title":"Gut-associated lymphoid tissue: a microbiota-driven hub of B cell immunity","volume":"45","author":"Bemark","year":"2024","journal-title":"Trends Immunol"},{"key":"10.1016\/j.kisu.2026.01.003_bib71","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.4772","article-title":"Association between tonsillectomy and outcomes in patients with immunoglobulin A nephropathy","volume":"2","author":"Hirano","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.kisu.2026.01.003_bib72","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000441852","article-title":"Tonsillectomy in a European cohort of 1,147 patients with IgA nephropathy","volume":"132","author":"Feehally","year":"2016","journal-title":"Nephron"},{"key":"10.1016\/j.kisu.2026.01.003_bib73","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00281-021-00879-4","article-title":"The immune landscape of IgA induction in the gut","volume":"43","author":"Seikrit","year":"2021","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.kisu.2026.01.003_bib74","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.34067\/KID.0002382022","article-title":"The gut and kidney crosstalk in immunoglobulin A nephropathy","volume":"3","author":"Sanchez-Russo","year":"2022","journal-title":"Kidney360"},{"key":"10.1016\/j.kisu.2026.01.003_bib75","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nri2322","article-title":"The regulation of IgA class switching","volume":"8","author":"Cerutti","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.kisu.2026.01.003_bib76","article-title":"The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies","volume":"3","author":"Cheung","year":"2023","journal-title":"Front Nephrol"},{"key":"10.1016\/j.kisu.2026.01.003_bib77","doi-asserted-by":"crossref","first-page":"394","DOI":"10.2215\/CJN.0000000000000338","article-title":"Targeting APRIL in the treatment of IgA nephropathy","volume":"19","author":"Cheung","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.003_bib78","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.kint.2024.08.012","article-title":"Targeting APRIL in the treatment of glomerular diseases","volume":"106","author":"Cheung","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.003_bib79","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3892\/mmr.2017.6190","article-title":"Expression profile of BAFF in peripheral blood from patients of IgA nephropathy: correlation with clinical features and Streptococcus pyogenes infection","volume":"15","author":"Zheng","year":"2017","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.kisu.2026.01.003_bib80","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/ndt\/gfaa264","article-title":"High levels of gut-homing immunoglobulin A+ B lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients","volume":"36","author":"Sallustio","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2026.01.003_bib81","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1681\/ASN.2015060677","article-title":"The role of TNF superfamily member 13 in the progression of IgA nephropathy","volume":"27","author":"Han","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.003_bib82","doi-asserted-by":"crossref","first-page":"683","DOI":"10.5301\/jn.5000218","article-title":"Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features","volume":"26","author":"Xin","year":"2013","journal-title":"J Nephrol"},{"key":"10.1016\/j.kisu.2026.01.003_bib83","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1681\/ASN.2006060658","article-title":"O-glycosylation of serum IgA1 antibodies against mucosal and systemic antigens in IgA nephropathy","volume":"17","author":"Smith","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.003_bib84","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/ki.2011.501","article-title":"An update on the pathogenesis and treatment of IgA nephropathy","volume":"81","author":"Boyd","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.003_bib85","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1093\/ndt\/gfae052","article-title":"IgA nephropathy: gut microbiome regulates the production of hypoglycosilated IgA1 via the TLR4 signaling pathway","volume":"39","author":"Zhu","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2026.01.003_bib86","article-title":"Immunoglobulin A nephropathy: molecular pathogenesis and targeted therapy","volume":"6","author":"Zhou","year":"2025","journal-title":"MedComm (2020)"},{"key":"10.1016\/j.kisu.2026.01.003_bib87","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/ndt\/gfy323","article-title":"Modulation of the microbiota by oral antibiotics treats immunoglobulin A nephropathy in humanized mice","volume":"34","author":"Chemouny","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2026.01.003_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.694787","article-title":"Fecal microbiota transplantation modulates renal phenotype in the humanized mouse model of IgA nephropathy","volume":"12","author":"Lauriero","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.kisu.2026.01.003_bib89","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1172\/JCI45563","article-title":"Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy","volume":"121","author":"McCarthy","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kisu.2026.01.003_bib90","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.34067\/KID.0000132021","article-title":"The gut and blood microbiome in IgA nephropathy and healthy controls","volume":"2","author":"Shah","year":"2021","journal-title":"Kidney360"},{"key":"10.1016\/j.kisu.2026.01.003_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107085","article-title":"Modifications of gut microbiota are associated with the severity of IgA nephropathy in the Chinese population","volume":"89","author":"Zhong","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.kisu.2026.01.003_bib92","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/ki.2015.94","article-title":"Gluten exacerbates IgA nephropathy in humanized mice through gliadin-CD89 interaction","volume":"88","author":"Papista","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.003_bib93","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/jcp.49.1.38","article-title":"Increased dimeric IgA producing B cells in the bone marrow in IgA nephropathy determined by in situ hybridisation for J chain mRNA","volume":"49","author":"Harper","year":"1996","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.kisu.2026.01.003_bib94","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1681\/ASN.2022020201","article-title":"Further evidence for the mucosal origin of pathogenic IgA in IgA nephropathy","volume":"33","author":"Cheung","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.003_bib95","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add6734","article-title":"Identification of IgA autoantibodies targeting mesangial cells redefines the pathogenesis of IgA nephropathy","volume":"9","author":"Nihei","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/j.kisu.2026.01.003_bib96","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.141289","article-title":"Immunoglobulin A nephropathy is characterized by anticommensal humoral immune responses","volume":"7","author":"Currie","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.kisu.2026.01.003_bib97","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1681\/ASN.2021081086","article-title":"Galactose-deficient IgA1 B cells in the circulation of IgA nephropathy patients carry preferentially lambda light chains and mucosal homing receptors","volume":"33","author":"Zachova","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.003_bib98","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adl6149","article-title":"The gut microbiota posttranslationally modifies IgA1 in autoimmune glomerulonephritis","volume":"16","author":"Gleeson","year":"2024","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.kisu.2026.01.003_bib99","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1172\/JCI20096","article-title":"Dysregulated LIGHT expression on T cells mediates intestinal inflammation and contributes to IgA nephropathy","volume":"113","author":"Wang","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kisu.2026.01.003_bib100","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.kisu.2026.01.003_bib101","author":"Calliditas Therapeutics"},{"key":"10.1016\/j.kisu.2026.01.003_bib102","series-title":"Kinpeygo (targeted release formulation budesonide) summary of product characteristics","author":"STADA Arzneimittel","year":"2024"},{"key":"10.1016\/j.kisu.2026.01.003_bib103","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.kisu.2026.03.001","article-title":"Norouzi S, Lafayette RA. Approved therapies in the IgA nephropathy armamentarium: a summary of the evidence","volume":"15","year":"2026","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kisu.2026.01.003_bib104","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.003_bib105","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3390\/jcm13010123","article-title":"An update on the genetics of IgA nephropathy","volume":"13","author":"Xu","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.kisu.2026.01.003_bib106","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1172\/JCI74475","article-title":"The genetics and immunobiology of IgA nephropathy","volume":"124","author":"Kiryluk","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kisu.2026.01.003_bib107","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2215\/CJN.07260713","article-title":"Glomerular diseases: emerging tests and therapies for IgA nephropathy","volume":"9","author":"Canetta","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.003_bib108","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1681\/ASN.2012010053","article-title":"Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy","volume":"23","author":"Berthoux","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.003_bib109","article-title":"Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression","volume":"14","author":"Maixnerova","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.kisu.2026.01.003_bib110","first-page":"1668","article-title":"Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity","volume":"119","author":"Suzuki","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kisu.2026.01.003_bib111","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1681\/ASN.2017060639","article-title":"Persistent microscopic hematuria as a risk factor for progression of IgA nephropathy: new floodlight on a nearly forgotten biomarker","volume":"28","author":"Coppo","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.003_bib112","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1523-1755.2005.67107.x","article-title":"IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells","volume":"67","author":"Novak","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.003_bib113","doi-asserted-by":"crossref","first-page":"ii28","DOI":"10.1093\/ckj\/sfad198","article-title":"Targeting complement in IgA nephropathy","volume":"16","author":"Caravaca-Font\u00e1n","year":"2023","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kisu.2026.01.003_bib114","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.638309","article-title":"Alternative complement pathway is activated and associated with galactose-deficient IgA(1) antibody in IgA nephropathy patients","volume":"12","author":"Chiu","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.kisu.2026.01.003_bib115","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000519973","article-title":"New insights into the pathogenesis and treatment strategies in IgA nephropathy","volume":"2","author":"Scionti","year":"2022","journal-title":"Glomerular Dis"},{"key":"10.1016\/j.kisu.2026.01.003_bib116","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/ndt\/gfy413","article-title":"Podocytopathy in the mesangial proliferative immunoglobulin A nephropathy: new insights into the mechanisms of damage and progression","volume":"34","author":"Trimarchi","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2026.01.003_bib117","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41392-023-01379-7","article-title":"Kidney fibrosis: from mechanisms to therapeutic medicines","volume":"8","author":"Huang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.kisu.2026.01.003_bib118","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0272-6386(96)90095-5","article-title":"Serologic study of immunoglobulin A-fibronectin aggregates in immunoglobulin A nephropathy","volume":"27","author":"Lai","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kisu.2026.01.003_bib119","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.3390\/jcm10204715","article-title":"The contribution of complement to the pathogenesis of IgA nephropathy: are complement-targeted therapies moving from rare disorders to more common diseases?","volume":"10","author":"Poppelaars","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.kisu.2026.01.003_bib120","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1093\/ndt\/gfac296","article-title":"The role of complement in glomerulonephritis-are novel therapies ready for prime time?","volume":"38","author":"Cheung","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2026.01.003_bib121","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s10157-021-02034-7","article-title":"Mesangial C3 deposition and serum C3 levels predict renal outcome in IgA nephropathy","volume":"25","author":"Wu","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.kisu.2026.01.003_bib122","article-title":"Decreased circulating C3 levels and mesangial C3 deposition predict renal outcome in patients with IgA nephropathy","volume":"7","author":"Kim","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.kisu.2026.01.003_bib123","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.kint.2023.04.029","article-title":"IgA nephropathy: the lectin pathway and implications for targeted therapy","volume":"104","author":"Barratt","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.003_bib124","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ekir.2017.11.015","article-title":"Progressive IgA nephropathy is associated with low circulating mannan-binding lectin-associated serine protease-3 (MASP-3) and increased glomerular factor H-related protein-5 (FHR5) deposition","volume":"3","author":"Medjeral-Thomas","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kisu.2026.01.003_bib125","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1186\/s12882-024-03832-3","article-title":"The prognostic role of activation of the complement pathways in the progression of advanced IgA nephropathy to end-stage renal disease","volume":"25","author":"Wang","year":"2024","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kisu.2026.01.003_bib126","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1681\/ASN.2005090923","article-title":"Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease","volume":"17","author":"Roos","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.003_bib127","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2215\/CJN.09710913","article-title":"Association of C4d deposition with clinical outcomes in IgA nephropathy","volume":"9","author":"Espinosa","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.003_bib128","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2215\/CJN.02530317","article-title":"Mesangial C4d deposits in early IgA nephropathy","volume":"13","author":"Segarra","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.003_bib129","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.xkme.2021.06.009","article-title":"Glomerular C4d deposition and kidney disease progression in IgA nephropathy: a systematic review and meta-analysis","volume":"3","author":"Jiang","year":"2021","journal-title":"Kidney Med"},{"key":"10.1016\/j.kisu.2026.01.003_bib130","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/s41379-019-0259-z","article-title":"Complement-mediated microangiopathy in IgA nephropathy and IgA vasculitis with nephritis","volume":"32","author":"Chua","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.kisu.2026.01.003_bib131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000381217","article-title":"Absence of mesangial C1q deposition is associated with resolution of proteinuria and hematuria after tonsillectomy plus steroid pulse therapy for immunoglobulin a nephropathy","volume":"130","author":"Nishiwaki","year":"2015","journal-title":"Nephron"},{"key":"10.1016\/j.kisu.2026.01.003_bib132","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.1038\/s41598-021-84715-7","article-title":"A multicenter, prospective, observational study to determine association of mesangial C1q deposition with renal outcomes in IgA nephropathy","volume":"11","author":"Tan","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.kisu.2026.01.003_bib133","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/MNH.0000000000000185","article-title":"Endothelin-1 and the kidney: new perspectives and recent findings","volume":"25","author":"De Miguel","year":"2016","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.kisu.2026.01.003_bib134","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/ki.2014.143","article-title":"Endothelin and endothelin antagonists in chronic kidney disease","volume":"86","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.003_bib135","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/MNH.0000000000000716","article-title":"Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease","volume":"30","author":"Smeijer","year":"2021","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.kisu.2026.01.003_bib136","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1681\/ASN.V12112321","article-title":"Renal endothelin-1 and endothelin receptor type B expression in glomerular diseases with proteinuria","volume":"12","author":"Lehrke","year":"2001","journal-title":"J Am Soc Nephrol"},{"issue":"suppl 6","key":"10.1016\/j.kisu.2026.01.003_bib137","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/ndt\/15.suppl_6.50","article-title":"Tubulointerstitial disease mediators of injury: the role of endothelin","volume":"15","author":"Benigni","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2026.01.003_bib138","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.kisu.2026.01.001","article-title":"Tang SCW, Reich HN. IgA nephropathy management: what does the future hold?","volume":"15","year":"2026","journal-title":"Kidney Int Suppl"}],"container-title":["Kidney International Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2157171626000031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2157171626000031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:50:21Z","timestamp":1785977421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2157171626000031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":134,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2157171626000031"],"URL":"https:\/\/doi.org\/10.1016\/j.kisu.2026.01.003","relation":{},"ISSN":["2157-1716"],"issn-type":[{"value":"2157-1716","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IgA nephropathy: an overview of the disease, its pathophysiology, and involvement of the gut-kidney axis","name":"articletitle","label":"Article Title"},{"value":"Kidney International Supplements","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2026.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2026.01.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2026.01.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2026.03.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2026.01.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2025.12.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}